Despoina Manousaki

Dr. Despoina Manousaki

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2021 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
DMDespoina Manousaki
Despoina Manousaki
AHAdil Harroud
Adil Harroud
RMRuth E. Mitchell
Ruth E. Mitchell
SRStephanie Ross
Stephanie Ross
VFVince Forgetta
Vince Forgetta
JRJ Brent Richards
J Brent Richards
Background: Vitamin D deficiency has been associated with type 1 diabetes in observational studies, but evidence from randomized controlled trials (RCTs) is lacking. The aim of this study was to test whether genetically decreased vitamin D levels are causally associated with type 1 diabetes using Mendelian randomization (MR). Methods and findings: For our two-sample MR study, we selected as instruments single nucleotide polymorphisms (SNPs) that are strongly associated with 25-hydroxyvitamin D (25OHD) levels in a large vitamin D genome-wide association study (GWAS) on 443,734 Europeans and obtained their corresponding effect estimates on type 1 diabetes risk from a large meta-analysis of 12 type 1 diabetes GWAS studies (Ntot = 24,063, 9,358 cases, and 15,705 controls). In addition to the main analysis using inverse variance weighted MR, we applied 3 additional methods to control for pleiotropy (MR-Egger, weighted median, and mode-based estimate) and compared the respective MR estimates. We also undertook sensitivity analyses excluding SNPs with potential pleiotropic effects. We identified 69 lead independent common SNPs to be genome-wide significant for 25OHD, explaining 3.1% of the variance in 25OHD levels. MR analyses suggested that a 1 standard deviation (SD) decrease in standardized natural log-transformed 25OHD (corresponding to a 29-nmol/l change in 25OHD levels in vitamin D–insufficient individuals) was not associated with an increase in type 1 diabetes risk (inverse-variance weighted (IVW) MR odds ratio (OR) = 1.09, 95% CI: 0.86 to 1.40, p = 0.48). We obtained similar results using the 3 pleiotropy robust MR methods and in sensitivity analyses excluding SNPs associated with serum lipid levels, body composition, blood traits, and type 2 diabetes. Our findings indicate that decreased vitamin D levels did not have a substantial impact on risk of type 1 diabetes in the populations studied. Study limitations include an inability to exclude the existence of smaller associations and a lack of evidence from non-European populations. Conclusions: Our findings suggest that 25OHD levels are unlikely to have a large effect on risk of type 1 diabetes, but larger MR studies or RCTs are needed to investigate small effects.

10 November 2021 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
NYNahid Yazdanpanah
Nahid Yazdanpanah
MYMojgan Yazdanpanah
Mojgan Yazdanpanah
YWYe Wang
Ye Wang
VFVincenzo Forgetta
Vincenzo Forgetta
MPMichael Pollak
Michael Pollak
DMDespoina Manousaki
Despoina Manousaki
OBJECTIVE To identify circulating proteins influencing type 1 diabetes susceptibility using Mendelian randomization (MR). RESEARCH DESIGN AND METHODS We used a large-scale two-sample MR study, using cis genetic determinants (protein quantitative trait loci [pQTL]) of up to 1,611 circulating proteins from five large genome-wide association studies, to screen for causal associations of these proteins with type 1 diabetes risk in 9,684 case subjects with type 1 diabetes and 15,743 control subjects. Further, pleiotropy-robust MR methods were used in sensitivity analyses using both cis and trans-pQTL. RESULTS We found that a genetically predicted SD increase in signal regulatory protein γ (SIRPG) level was associated with increased risk of type 1 diabetes risk (MR odds ratio [OR] 1.66 [95% 1.36–2.03]; P = 7.1 × 10−7). The risk of type 1 diabetes increased almost twofold per genetically predicted standard deviation (SD) increase in interleukin-27 Epstein-Barr virus–induced 3 (IL27-EBI3) protein levels (MR OR 1.97 [95% CI 1.48–2.62]; P = 3.7 × 10−6). However, an SD increase in chymotrypsinogen B1 (CTRB1) was associated with decreased risk of type 1 diabetes (MR OR 0.84 [95% CI 0.77–0.90]; P = 6.1 × 10−6). Sensitivity analyses using MR methods testing for pleiotropy while including trans-pQTL showed similar results. While the MR-Egger suggested no pleotropic effect (P value MR-Egger intercept = 0.31), there was evidence of pleiotropy in MR-PRESSO (P value global test = 0.006). CONCLUSIONS We identified three novel circulating protein biomarkers associated with type 1 diabetes risk using an MR approach. These biomarkers are promising targets for development of drugs and/or of screening tools for early prediction of type 1 diabetes.

2 March 2022 in Diabetes
Verified
Journal Article
Closed access
PDF file
FGFaegheh Ghanbari
Faegheh Ghanbari
NYNahid Yazdanpanah
Nahid Yazdanpanah
MYMojgan Yazdanpanah
Mojgan Yazdanpanah
JRJ. Brent Richards
J. Brent Richards
DMDespoina Manousaki
Despoina Manousaki
Type 2 diabetes shows an increasing prevalence in both adults and children. Identification of biomarkers for both youth and adult-onset type 2 diabetes is crucial for development of screening tools or drug targets. In this study, using two-sample Mendelian randomization (MR), we identified 22 circulating proteins causally linked to adult type 2 diabetes and 11 proteins with suggestive evidence for association with youth-onset type 2 diabetes. Among these, colocalization analysis further supported a role in type 2 diabetes for C-type mannose receptor 2 (MR odds ratio [OR] 0.85 [95% CI 0.79–0.92] per genetically predicted SD increase in protein level), MANS domain containing 4 (MR OR 0.90 [95% CI 0.88–0.92]), sodium/potassium-transporting ATPase subunit β2 (MR OR 1.10 [95% CI 1.06–1.15]), endoplasmic reticulum oxidoreductase 1β (MR OR 1.09 [95% CI 1.05–1.14]), spermatogenesis-associated protein 20 (MR OR 1.12 [95% CI 1.06–1.18]), haptoglobin (MR OR 0.96 [95% CI 0.94–0.98]), and α1–3-N-acetylgalactosaminyltransferase and α1–3-galactosyltransferase (MR OR 1.04 [95% CI 1.03–1.05]). Our findings support a causal role in type 2 diabetes for a set of circulating proteins, which represent promising type 2 diabetes drug targets.

1 December 2019 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
JKJulyan Keller-Baruch
Julyan Keller-Baruch
VFVincenzo Forgetta
Vincenzo Forgetta
DMDespoina Manousaki
Despoina Manousaki
SZSirui Zhou
Sirui Zhou
JRJ Brent Richards
J Brent Richards
Vascular endothelial growth factor (VEGF) is important for bone formation and has been associated with osteoporosis in humans. Therefore, we conducted a two-sample Mendelian randomization study to test whether genetically decreased circulating VEGF was associated with decreased bone mineral density (BMD) and increased risk of fracture. Summary statistics from a genomewide association study (GWAS) meta-analysis of circulating VEGF level (n = 16,112) were used to identify 10 genetic variants explaining up to 52% of the variance in circulating VEGF levels. GWAS meta-analyses on dual-energy X-ray absorptiometry (DXA)-derived BMD of forearm, lumbar spine, and femoral neck (n = up to 32,735) and BMD estimated from heel calcaneus ultrasound (eBMD) (n = 426,824) were used to assess the effect of genetically lowered circulating VEGF levels on BMD. A GWAS meta-analysis including a total of 76,549 cases and 470,164 controls was used to assess the effect of genetically lowered circulating VEGF levels on risk of fracture. A natural log-transformed pg/mL decrease in circulating VEGF levels was not associated with a decrease in forearm BMD (0.02 standard deviation [SD], 95% confidence interval [CI] −0.024 to 0.064, p = 0.38), lumbar spine BMD (−0.005 SD, 95% CI −0.03 to 0.019, p = 0.67), femoral neck BMD (0.004 SD, 95% CI −0.017 to 0.026, p = 0.68), eBMD (−0.006 SD, 95% CI −0.012 to −0.001, p = 0.031) or risk of fracture (odds ratio = 0.99, 95% CI 0.98 to 1.0, p = 0.37) in inverse-variance–weighted Mendelian randomization analyses. Sensitivity analyses did not provide evidence that our results were influenced by pleiotropy. Genetically lowered circulating VEGF was not associated with a decrease in BMD or increased risk of fracture, suggesting that efforts to influence circulating VEGF level are unlikely to have beneficial effects on osteoporosis outcomes and that previous observational associations of circulating VEGF with BMD were influenced by confounding or reverse causation. © 2019 American Society for Bone and Mineral Research.

13 December 2022 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
MAManel Adi
Manel Adi
FGFaegheh Ghanbari
Faegheh Ghanbari
MDMallory L Downie
Mallory L Downie
AHAdriana Hung
Adriana Hung
CRCassiane Robinson-Cohen
Cassiane Robinson-Cohen
DMDespoina Manousaki
Despoina Manousaki
Background Observational studies investigating the role of vitamin D in renal function have yielded inconsistent results. We tested whether 25-hydroxyvitamin D [25(OH)D] serum levels are associated with renal function, and inversely, whether altered renal function causes changes in 25(OH)D, using Mendelian randomization (MR). Methods In this two-sample MR study, we used single nucleotide polymorphisms (SNP) associated with 25(OH)D in 443,734 Europeans, and their effects on eGFR, Blood Urea Nitrogen [BUN], chronic kidney disease [CKD] risk and progression in genome-wide association studies totaling over 1 million Europeans. To control for pleiotropy, we also used SNPs solely in DHCR7, CYP2R1, GC, all genes with known roles in vitamin D metabolism. We performed a reverse MR, using SNPs for the above indices of renal function to study causal effects on 25(OH)D levels. Results We did not find robust evidence supporting effects of 25(OH)D on eGFR, BUN, and CKD or its progression. Our inverse variance weighted MR demonstrated a 0.56 decrease in standardized log-transformed 25(OH)D (95% CI = -0.73, -0.41 P = 2.89 x10−12) per unit increase in log-transformed eGFR. Increased BUN was associated with increased 25(OH)D (β = 0.25, 95% CI = 0.15, 0.36, P = 4.12 × 10−6 per unit increase in log-transformed BUN). Finally, genetically predicted CKD conferred a 0.05 increase in standardized log-transformed 25(OH)D level (95% CI = 0.04,0.06, P = 1.06 x10−13). Other MR methods confirmed the findings of the main analyses. Conclusions Genetically predicted CKD, increased BUN and decreased eGFR are associated with increased 25(OH)D levels, but we found no causal effect of 25(OH)D on renal function in Europeans.

5 October 2023 in JBMR Plus
Verified
Journal Article
Open access
FGFaegheh Ghanbari
Faegheh Ghanbari
NONao Otomo
Nao Otomo
IGIsabel Gamache
Isabel Gamache
TITakuro Iwami
Takuro Iwami
YKYoshinao Koike
Yoshinao Koike
DMDespoina Manousaki
Despoina Manousaki
Adolescent idiopathic scoliosis (AIS) is the most common form of pediatric musculoskeletal disorder. Observational studies have pointed to several risk factors for AIS, but almost no evidence exists to support their causal association with AIS. Here, we applied Mendelian randomization (MR), known to limit bias from confounding and reverse causation, to investigate causal associations between body composition and puberty‐related exposures and AIS risk in Europeans and Asians. For our two‐sample MR studies, we used single nucleotide polymorphisms (SNPs) associated with body mass index (BMI), waist‐hip ratio, lean mass, childhood obesity, bone mineral density (BMD), 25‐hydroxyvitamin D (25OHD), age at menarche, and pubertal growth in large European genome‐wide association studies (GWAS), and with adult osteoporosis risk and age of menarche in Biobank Japan. We extracted estimates of the aforementioned SNPs on AIS risk from the European or Asian subsets of the largest multiancestry AIS GWAS (N = 7956 cases/88,459 controls). The results of our inverse variance‐weighted (IVW) MR estimates suggest no causal association between the aforementioned risk factors and risk of AIS. Pleiotropy‐sensitive MR methods yielded similar results. However, restricting our analysis to European females with AIS, we observed a causal association between estimated BMD and the risk of AIS (IVW odds ratio for AIS = 0.1, 95% confidence interval 0.01 to 0.7, p = 0.02 per SD increase in estimated BMD), but this association was no longer significant after adjusting for BMI, body fat mass, and 25OHD and remained significant after adjusting for age at menarche in multivariable MR. In conclusion, we demonstrated a protective causal effect of BMD on AIS risk in females of European ancestry, but this effect was modified by BMI, body fat mass, and 25OHD levels. Future MR studies using larger AIS GWAS are needed to investigate small effects of the aforementioned exposures on AIS. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.